Previous 10 | Next 10 |
NEWARK, Calif., June 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that, due to public health and safety...
Shares of CymaBay Therapeutics (NASDAQ: CBAY) have climbed nearly 143% since last week after it got great news about its orphan drug, seladelpar. A phase 2B trial for the drug to see how it did against nonalcoholic steatohepatitis (NASH, or liver inflammation not caused by alcohol) ha...
Gainers: CymaBay Therapeutics (NASDAQ: CBAY ) +134% . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., Babcock & Wilcox Enterprises, Inc., Stocks on the move, , Read more ...
CymaBay Therapeutics (NASDAQ: CBAY ) +147% on upgrades and Q1 results . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., NanoViricides, Inc., News on the U.S. economy Read more ...
"Seledelpar is back," says Raymond James, upgrading CymaBay Therapeutics (NASDAQ: CBAY ) to Outperform after last night's "stunning" news on the treatment. More news on: CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Image source: The Motley Fool. CymaBay Therapeutics Inc (NASDAQ: CBAY) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
CymaBay Therapeutics, Inc. (CBAY) Q1 2020 Earnings Conference Call May 11, 2020 04:30 PM ET Company Participants Dan Menold - Vice President, Finance Sujal Shah - President and Chief Executive Officer Charles McWherter - Senior Vice President and Chief Scientific Officer Klara ...
CymaBay Therapeutics (NASDAQ: CBAY ) +111.9% after-hours following the company's smaller than forecast Q1 loss and news that an "independent expert panel" unanimously agreed that there is no clinical, biochemical or histological evidence of liver injury induced by its seladelpar liv...
Are These On Your List Of Penny Stocks To Watch This Week? It can be tough at times to trade penny stocks . Some days there are only a few names to choose from. But there are other days where there seems to be plenty of penny stocks to buy . In either case, having your plan in place can defi...
Gainers: CBAY +73.4% . NVAX +42.9% . YRCW +39.2% . IIVI +21.5% . BHF +13.9% . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., YRC Worldwide Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...